Links for fulltext
     (May Require Subscription)
Supplementary

Article: Survival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infection

TitleSurvival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infection
Authors
Issue Date2014
Citation
Hepatobiliary Surgery and Nutrition, 2014, v. 3 n. 4, p. 185-193 How to Cite?
AbstractIntroduction: For patients with resectable hepatocellular carcinoma (HCC), hepatectomy remains one of the best treatment options to provide long-term survival. However, more than 50% of the patients have unresectable disease upon diagnosis even though there are no distant metastases. Transarterial chemoembolization (TACE) is a well-established treatment option that offers a palliative survival benefit for this group of patients. A better treatment for unresectable HCC has been sought after. There is some evidence that transarterial radioembolization (TARE) with the agent yttrium-90 produces encouraging outcomes, especially in patients with portal vein tumor thrombus. This study aims to analyze the outcomes of TARE at our center. Methods: From August 2009 to April 2013, 16 patients underwent TARE at our center. Sixteen patients with similar tumor characteristics were selected to undergo TACE alone for comparison. A retrospective analysis of the prospectively collected data of the patients was conducted. Only patients with newly diagnosed primary tumors were included in this study. Results: The median survival for patients having TARE was 19.9 versus 14.0 months in the TACE group (P=0.615). There was no difference in terms of tumor response according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) (P=0.632). The 1-, 2- and 3-year survival rates in the TARE group were 80.0%, 30.5% and 20.3% respectively. The 1-year survival in the TACE group was 58.3% (P=0.615). For patients who had major vascular invasion (eight in each group), the 1- and 2-year survival rates in the TARE group were 62.5% and 15.6% respectively, while the 1-year survival in the TACE group was 35.0% (P=0.664). Conclusions: The two groups showed similar results in terms of tumor response and overall survival benefit. TARE might provide a survival benefit for patients with major vessel invasion.
Persistent Identifierhttp://hdl.handle.net/10722/202749
PubMed Central ID

 

DC FieldValueLanguage
dc.contributor.authorShe, WHen_US
dc.contributor.authorCheung, TTen_US
dc.contributor.authorYau, TCCen_US
dc.contributor.authorChan, ACYen_US
dc.contributor.authorChok, KSHen_US
dc.contributor.authorChu, SKFen_US
dc.contributor.authorLiu, KYen_US
dc.contributor.authorPoon, RTPen_US
dc.contributor.authorChan, SCen_US
dc.contributor.authorFan, STen_US
dc.contributor.authorLo, CMen_US
dc.date.accessioned2014-09-19T09:33:35Z-
dc.date.available2014-09-19T09:33:35Z-
dc.date.issued2014en_US
dc.identifier.citationHepatobiliary Surgery and Nutrition, 2014, v. 3 n. 4, p. 185-193en_US
dc.identifier.urihttp://hdl.handle.net/10722/202749-
dc.description.abstractIntroduction: For patients with resectable hepatocellular carcinoma (HCC), hepatectomy remains one of the best treatment options to provide long-term survival. However, more than 50% of the patients have unresectable disease upon diagnosis even though there are no distant metastases. Transarterial chemoembolization (TACE) is a well-established treatment option that offers a palliative survival benefit for this group of patients. A better treatment for unresectable HCC has been sought after. There is some evidence that transarterial radioembolization (TARE) with the agent yttrium-90 produces encouraging outcomes, especially in patients with portal vein tumor thrombus. This study aims to analyze the outcomes of TARE at our center. Methods: From August 2009 to April 2013, 16 patients underwent TARE at our center. Sixteen patients with similar tumor characteristics were selected to undergo TACE alone for comparison. A retrospective analysis of the prospectively collected data of the patients was conducted. Only patients with newly diagnosed primary tumors were included in this study. Results: The median survival for patients having TARE was 19.9 versus 14.0 months in the TACE group (P=0.615). There was no difference in terms of tumor response according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) (P=0.632). The 1-, 2- and 3-year survival rates in the TARE group were 80.0%, 30.5% and 20.3% respectively. The 1-year survival in the TACE group was 58.3% (P=0.615). For patients who had major vascular invasion (eight in each group), the 1- and 2-year survival rates in the TARE group were 62.5% and 15.6% respectively, while the 1-year survival in the TACE group was 35.0% (P=0.664). Conclusions: The two groups showed similar results in terms of tumor response and overall survival benefit. TARE might provide a survival benefit for patients with major vessel invasion.-
dc.languageengen_US
dc.relation.ispartofHepatobiliary Surgery and Nutritionen_US
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.titleSurvival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infectionen_US
dc.typeArticleen_US
dc.identifier.emailCheung, TT: cheung68@hku.hken_US
dc.identifier.emailYau, TCC: tyaucc@hku.hken_US
dc.identifier.emailChan, ACY: acchan@hku.hken_US
dc.identifier.emailChok, KSH: chok6275@hku.hken_US
dc.identifier.emailChu, SKF: fchu@hkucc.hku.hken_US
dc.identifier.emailLiu, KY: ricoliu@hkucc.hku.hken_US
dc.identifier.emailPoon, RTP: poontp@hku.hken_US
dc.identifier.emailChan, SC: chanlsc@hkucc.hku.hken_US
dc.identifier.emailFan, ST: stfan@hku.hken_US
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hken_US
dc.identifier.authorityYau, TCC=rp01466en_US
dc.identifier.authorityChan, ACY=rp00310en_US
dc.identifier.authorityPoon, RTP=rp00446en_US
dc.identifier.authorityChan, SC=rp01568en_US
dc.identifier.authorityFan, ST=rp00355en_US
dc.identifier.authorityLo, CM=rp00412en_US
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3978/j.issn.2304-3881.2014.07.09en_US
dc.identifier.pmid25202695-
dc.identifier.pmcidPMC4141294-
dc.identifier.hkuros239993en_US
dc.identifier.volume3en_US
dc.identifier.issue4en_US
dc.identifier.spage185en_US
dc.identifier.epage193en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats